Avanos Medical (NYSE: AVNS) CEO receives new stock options and RSUs

Rhea-AI Filing Summary

Avanos Medical, Inc. reported that Chief Executive Officer David Pacitti received new equity awards. He was granted employee stock options for 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.

Pacitti also received 101,341 time-based restricted share units under the 2021 Long Term Incentive Plan. These restricted units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, and each unit is the economic equivalent of one share of Common Stock. Following these grants, he holds 343,388 shares of Common Stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacitti David

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GA 30004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		101,341(1)	A	$0	343,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		239,354		(2)	03/13/2036	Common Stock	239,354	$0	239,354	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

	/s/ John Hurley, as attorney-in-fact for David Pacitti	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did AVNS CEO David Pacitti receive in this Form 4?

David Pacitti received 239,354 employee stock options and 101,341 time-based restricted share units. The options carry a $13.69 exercise price, while each restricted unit represents the economic equivalent of one Avanos Medical Common Share, reflecting compensation-based, not open-market, acquisitions.

How do the new stock options for AVNS CEO David Pacitti vest and expire?

Pacitti’s employee stock options cover 239,354 Avanos shares at $13.69 per share and expire on March 13, 2036. According to the disclosure, the options vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029.

What are the terms of the restricted share units granted to AVNS CEO Pacitti?

Pacitti received 101,341 time-based restricted share units under Avanos’ 2021 Long Term Incentive Plan. These vest one-third on March 13, 2027, one-third on March 13, 2028, and one-third on March 13, 2029. Each unit is economically equivalent to one share of Common Stock.

How many AVNS common shares does CEO David Pacitti hold after these grants?

After these equity awards, Pacitti directly holds 343,388 shares of Avanos Medical Common Stock. This figure reflects his updated direct ownership position reported in the Form 4, incorporating the new grant of 101,341 restricted share units as an acquisition entry.

Is the AVNS CEO’s Form 4 transaction a market purchase or a compensation grant?

The transactions reported are compensation-related grants, not open-market purchases. They are coded as awards: employee stock options with a fixed exercise price and time-based restricted share units, all granted under Avanos Medical’s 2021 Long Term Incentive Plan, as amended.